March 27th, 20252025-03-27Takeda’s HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP) January 29th, 20252025-01-29Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age All News